ResApp Health (ASX:RAP) grants Sanofi an option to licence startup outcomes

Company News

by Katrina Bullock

Digital health company ResApp Health (ASX:RAP) has penned an agreement which grants Sanofi an exclusive license to use the outcomes generated under the Startup Creasphere incubator program.

Under this program the 2 companies are collaborating on building a smartphone application which will leverage ResApp’s novel cough-based diagnostic system to provide at-home support to consumers.

ResApp has granted Sanofi the option to negotiate and acquire exclusive rights to develop, manufacture and commercialise a respiratory disease self-assessment application specifically for consumers.

Shares in ResApp Health (ASX:RAP) are trading 1.9 per cent higher at 28 cents.